CIMAVaxG vaccine (NGcGM3/VSSP vaccine) / Recombio, Center of Molecular Immunology - LARVOL DELTA

The tumor antigen N-glycolyl-GM3 is a human CD1d ligand capable of mediating B cell and natural killer T cell interaction. (PubMed) - Cancer Immunol Immunother - "Our findings identify a novel, endogenous, human CD1d ligand, which is sufficiently competent to stimulate iNKT. We postulate that CD1d-restricted Bc presentation of NGcGM3 drives effective iNKT activation, an immunological mechanism that has not been previously described for humans, which may contribute to understanding aNGcGM3 occurrence."

Journal • Biosimilar • Oncology